Yarrow Bioscience stake reported by Logos Global

Yarrow Bioscience, Inc. has a significant shareholder group led by Logos Global Management LP and related entities, which report beneficial ownership of up to 9.9% of the company’s common stock.

Rhea-AI Filing Summary

Yarrow Bioscience, Inc. has a significant shareholder group led by Logos Global Management LP and related entities, which report beneficial ownership of up to 9.9% of the company’s common stock. This stake is held through combinations of common shares and prefunded warrants, all subject to a 9.99% beneficial ownership limitation.

The ownership percentages are calculated using 2,669,788 shares of common stock outstanding as of July 29, 2026. The reporting persons state that the securities are not held for the purpose of changing or influencing control and that they disclaim beneficial ownership beyond their pecuniary interests.

Key Figures

Shares outstanding: 2,669,788 shares Beneficial ownership percentage: 9.9% Logos Global beneficial ownership: 276,704 shares +4 more

7 metrics

Shares outstanding 2,669,788 shares Common stock outstanding as of July 29, 2026 used to calculate ownership

Beneficial ownership percentage 9.9% Reported percent of class for each Logos-related reporting person

Logos Global beneficial ownership 276,704 shares Amount beneficially owned by Logos Global and Logos Global GP

Global Fund beneficial ownership 120,026 shares Amount beneficially owned by Logos Global Master Fund LP and Logos GP LLC

Opportunities Fund V beneficial ownership 256,704 shares Amount beneficially owned by Logos Opportunities Fund V LP and its GP

Prefunded warrants block 2,201,030 shares Shares of common stock acquirable via prefunded warrants in one Logos Global block

Beneficial ownership cap 9.99% Beneficial ownership limitation applied to prefunded warrants

Key Terms

prefunded warrants, beneficial ownership limitation, beneficial owner, pecuniary interest, +2 more

6 terms

prefunded warrants financial

"shares of Common Stock and prefunded warrants to acquire 2,201,030 shares"

Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.

beneficial ownership limitation regulatory

"prefunded warrants to acquire 2,201,030 shares of Common Stock, subject to a 9.99% beneficial ownership limitation"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

beneficial owner regulatory

"it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

pecuniary interest financial

"Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein"

investment adviser financial

"Logos Global is the investment adviser to investment funds, including Global Fund and Opp V"

An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

Schedule 13D or 13G regulatory

"AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in Yarrow Bioscience (VYNE) does Logos Global report?

Logos Global and related entities report beneficial ownership of up to 9.9% of Yarrow Bioscience’s common stock, based on 2,669,788 shares outstanding as of July 29, 2026, including common shares and prefunded warrants.

How many Yarrow Bioscience (VYNE) shares and warrants does Logos Global’s group hold?

Holdings include blocks such as 176,678 common shares plus prefunded warrants to acquire 2,201,030 shares, all subject to a 9.99% beneficial ownership limitation, with reported beneficial ownership capped at 9.9% of the outstanding common stock.

What share count did Yarrow Bioscience (VYNE) use to calculate ownership percentages?

Ownership percentages are calculated using 2,669,788 shares of Yarrow Bioscience common stock outstanding as of July 29, 2026, as referenced from a Form 8-K filed on July 30, 2026.

Are Logos Global’s Yarrow Bioscience (VYNE) holdings intended to influence control?

The reporting persons certify that the securities were not acquired and are not held to change or influence control of Yarrow Bioscience and are not held in connection with any transaction having that purpose or effect.

Who ultimately benefits from Logos Global’s Yarrow Bioscience (VYNE) holdings?

Each of Global Fund and Opportunities Fund V holds Yarrow Bioscience common stock for the benefit of its investors and has the right to receive or direct dividends and sale proceeds from these securities.

What is the beneficial ownership limitation on Yarrow Bioscience (VYNE) prefunded warrants?

The prefunded warrants held by the Logos Global-affiliated funds are subject to a 9.99% beneficial ownership limitation, restricting exercises that would increase beneficial ownership above that threshold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 02:13 PM Accepted by SEC EDGAR 08/04/2026 - 02:12 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Yarrow Bioscience, Inc.

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)

92941V407

(CUSIP Number)

07/27/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Logos Global Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 276,704.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 276,704.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

276,704.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: The shares reported herein consist of 176,678 shares of Common Stock and prefunded warrants to acquire 2,201,030 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage is calculated based on 2,669,788 shares of Common Stock outstanding on July 29, 2026, as reported in the Form 8-K filed by the Issuer on July 30, 2026.

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Logos Global Management GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 276,704.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 276,704.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

276,704.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, OO

Comment for Type of Reporting Person: The shares reported herein consist of 176,678 shares of Common Stock and prefunded warrants to acquire 2,201,030 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage is calculated based on 2,669,788 shares of Common Stock outstanding on July 29, 2026, as reported in the Form 8-K filed by the Issuer on July 30, 2026.

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Logos Global Master Fund LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 120,026.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 120,026.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

120,026.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The shares reported herein consist of 20,000 shares of Common Stock and prefunded warrants to acquire 906,090 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage is calculated based on 2,669,788 shares of Common Stock outstanding on July 29, 2026, as reported in the Form 8-K filed by the Issuer on July 30, 2026.

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Logos GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 120,026.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 120,026.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

120,026.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, OO

Comment for Type of Reporting Person: The shares reported herein consist of 20,000 shares of Common Stock and prefunded warrants to acquire 906,090 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage is calculated based on 2,669,788 shares of Common Stock outstanding on July 29, 2026, as reported in the Form 8-K filed by the Issuer on July 30, 2026.

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Logos Opportunities Fund V LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 256,704.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 256,704.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

256,704.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The shares reported herein consist of 156,678 shares of Common Stock and prefunded warrants to acquire 1,294,940 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage is calculated based on 2,669,788 shares of Common Stock outstanding on July 29, 2026, as reported in the Form 8-K filed by the Issuer on July 30, 2026.

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Logos Opportunities V GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 256,704.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 256,704.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

256,704.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, OO

Comment for Type of Reporting Person: The shares reported herein consist of 156,678 shares of Common Stock and prefunded warrants to acquire 1,294,940 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage is calculated based on 2,669,788 shares of Common Stock outstanding on July 29, 2026, as reported in the Form 8-K filed by the Issuer on July 30, 2026.

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Arsani William

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 276,704.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 276,704.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

276,704.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: The shares reported herein consist of 176,678 shares of Common Stock and prefunded warrants to acquire 2,201,030 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage is calculated based on 2,669,788 shares of Common Stock outstanding on July 29, 2026, as reported in the Form 8-K filed by the Issuer on July 30, 2026.

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Graham Walmsley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 256,704.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 256,704.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

256,704.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: The shares reported herein consist of 156,678 shares of Common Stock and prefunded warrants to acquire 1,294,940 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage is calculated based on 2,669,788 shares of Common Stock outstanding on July 29, 2026, as reported in the Form 8-K filed by the Issuer on July 30, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Yarrow Bioscience, Inc.
(b)	Address of issuer's principal executive offices: 470 James Street, Suite 007, New Haven, CT 06513
Item 2.
(a)	Name of person filing: Logos Global Management LP ("Logos Global") Logos Global Management GP LLC ("Logos Global GP") Logos Global Master Fund LP ("Global Fund") Logos GP LLC ("Logos GP") Logos Opportunities Fund V LP ("Opp V") Logos Opportunities V GP LLC ("Opp V GP") Arsani William Graham Walmsley Logos Global is the investment adviser to investment funds, including Global Fund and Opp V. Logos Global GP is the general partner of Logos Global. Logos GP is the general partner of Global Fund. Opp V GP is the general partner of Opp V. Dr. William is a control person of Logos Global, Logos Global GP and Logos GP. Dr. William and Dr. Walmsley are the control persons of Opp V GP. The reporting persons are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Global Fund or Opp Fund V should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
(b)	Address or principal business office or, if none, residence: One Letterman Drive, Building C, Suite C3-350, San Francisco, California 94129
(c)	Citizenship: See Item 4 of the cover sheet for each reporting person.
(d)	Title of class of securities: Common Stock, par value $0.0001
(e)	CUSIP Number(s): 92941V407
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Logos Global: 276,704 Logos Global GP: 276,704 Global Fund: 120,026 Logos GP: 120,026 Opp V: 256,704 Opp V GP: 256,704 Arsani William: 276,704 Graham Walmsley: 256,704
(b)	Percent of class: Logos Global: 9.9% Logos Global GP: 9.9% Global Fund: 9.9% Logos GP: 9.9% Opp V: 9.9% Opp V GP: 9.9% Arsani William: 9.9% Graham Walmsley: 9.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Logos Global: 0 Logos Global GP: 0 Global Fund: 0 Logos GP: 0 Opp V: 0 Opp V GP: 0 Graham Walmsley: 0 Arsani William: 0
	(ii) Shared power to vote or to direct the vote: Logos Global: 276,704 Logos Global GP: 276,704 Global Fund: 120,026 Logos GP: 120,026 Opp V: 256,704 Opp V GP: 256,704 Arsani William: 276,704 Graham Walmsley: 256,704
	(iii) Sole power to dispose or to direct the disposition of: Logos Global: 0 Logos Global GP: 0 Global Fund: 0 Logos GP: 0 Arsani William: 0
	(iv) Shared power to dispose or to direct the disposition of: Logos Global: 276,704 Logos Global GP: 276,704 Global Fund: 120,026 Logos GP: 120,026 Opp V: 256,704 Opp V GP: 256,704 Arsani William: 276,704 Graham Walsmley: 256,704
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Each of Global Fund and Opp V hold the Common Stock for the benefit of each of its respective investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Logos Global Management LP

Signature:	/s/ Arsani William
Name/Title:	Managing Partner
Date:	08/03/2026

Logos Global Management GP LLC

Signature:	/s/ Arsani William
Name/Title:	Managing Member
Date:	08/03/2026

Logos Global Master Fund LP

Signature:	/s/ Arsani William
Name/Title:	Managing Member of Logos GP LLC, General Partner of Logos Global Master Fund LP
Date:	08/03/2026

Logos GP LLC

Signature:	/s/ Arsani William
Name/Title:	Managing Member
Date:	08/03/2026

Logos Opportunities Fund V LP

Signature:	/s/ Graham Walmsley
Name/Title:	Managing Member of Logos Opportunities V GP LLC, General Partner of Logos Opportunities Fund V LP
Date:	08/03/2026

Logos Opportunities V GP LLC

Signature:	/s/ Graham Walmsley
Name/Title:	Managing Member
Date:	08/03/2026

Arsani William

Signature:	/s/ Arsani William
Name/Title:	Reporting person
Date:	08/03/2026

Graham Walmsley

Signature:	/s/ Graham Walmsley
Name/Title:	Reporting person
Date:	08/03/2026

Exhibit Information

EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G